BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a report on Wednesday, November 6th.

BioLineRx Trading Down 1.5 %

Shares of NASDAQ:BLRX opened at $0.44 on Friday. The firm has a fifty day moving average of $0.53 and a two-hundred day moving average of $0.63. The firm has a market capitalization of $35.54 million, a P/E ratio of -0.99 and a beta of 1.48. BioLineRx has a 12-month low of $0.39 and a 12-month high of $1.93. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. On average, equities analysts expect that BioLineRx will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp acquired a new position in BioLineRx in the second quarter valued at about $70,000. CVI Holdings LLC bought a new position in BioLineRx in the 2nd quarter valued at $462,000. Finally, Atria Investments Inc increased its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares during the period. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.